Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 5/20 | 0.64 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA3 | P07451 | 1/20 | 0.61 |
| ▸ | CA4 | P22748 | 1/20 | 0.61 |
| ▸ | CA6 | P23280 | 1/20 | 0.61 |
| ▸ | CA5A | P35218 | 1/20 | 0.61 |
| ▸ | CA7 | P43166 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.61 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.61 |
| ▸ | GPR35 | Q9HC97 | 5/20 | 0.52 |
| ▸ | CNR2 | P34972 | 3/20 | 0.49 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1654658 | 0.90 | CA12 (0.64) | S1PR1CA12CA1CA2CA3 | |
| SCHEMBL3330816 | 0.87 | S1PR1 (0.61) | S1PR1CA12CA2CA3CA4 | |
| SCHEMBL3880404 | 0.85 | S1PR1 (0.49) | S1PR1CA12CA1CA2CA3 | |
| SCHEMBL14322156 | 0.81 | S1PR1 (0.84) | S1PR1CNR2ALDH1A1MAOAKMT2A | |
| SCHEMBL14322300 | 0.81 | S1PR1 (0.68) | S1PR1CNR2MAOAMAPK1 | |
| SCHEMBL1406414 | 0.80 | CA12 (0.68) | CA12CA1CA2CA3CA4 | |
| SCHEMBL982766 | 0.80 | CA12 (0.68) | CA12CA1CA2CA3CA4 | |
| SCHEMBL1654636 | 0.80 | CA12 (0.61) | CA12CA1CA2CA3CA4 | |
| SCHEMBL1656813 | 0.80 | S1PR1 (0.81) | S1PR1CNR2ALDH1A1MAOAKMT2A | |
| SCHEMBL1653783 | 0.80 | S1PR1 (0.81) | S1PR1CNR2ALDH1A1MAOAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9572792-B2 | Coumarin compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150265573-A1 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. | 2015-09-24 | — | — | US | disclosed |
| US-9073888-B2 | Coumarin compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2491023-B1 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN INC (US) | 2014-12-31 | — | — | EP | disclosed |
| US-20120328661-A1 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| EP-2491023-A2 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | Allergan, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011050054-A2 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20100144729-A1 | COUMARIN DERIVATIVES | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | disclosed |
| US-20100144729-A1 | COUMARIN DERIVATIVES | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | disclosed |
| US-20100144729-A1 | COUMARIN DERIVATIVES | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | disclosed |
| US-20090318546-A1 | Chromen-2-One Derivatives | NOVARTIS AG (CH) | 2009-12-24 | — | — | US | disclosed |
| EP-2109606-A1 | CHROMENE S1P1 RECEPTOR ANTAGONIST | Novartis Ag (CH) | 2009-10-21 | — | — | EP | disclosed |
| EP-2010511-A1 | CHROMEN-2-ONE DERIVATIVES | Novartis AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| WO-2008092930-A1 | CHROMENE S1P1 RECEPTOR ANTAGONIST | NOVARTIS AG (CH) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008092930-A1 | CHROMENE S1P1 RECEPTOR ANTAGONIST | NOVARTIS AG (CH) | 2008-08-07 | — | — | WO | disclosed |
| WO-2007115820-A1 | CHROMEN-2-ONE DERIVATIVES | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150265573-A1 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR3, S1PR1, S1PR2 | S1PR1 2/4885CA12 4409/4885CA1 4396/4885 |
| US-20090318546-A1 | Chromen-2-One Derivatives | CYP1A2, CYP4B1, CYP1B1 | S1PR1 3084/4885CA12 3337/4885CA1 4633/4885 |
| US-20100144729-A1 | COUMARIN DERIVATIVES | F3, CYP3A7, CYP3A4 | S1PR1 3766/4885CA12 3680/4885CA1 4141/4885 |
| US-20120328661-A1 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR3, S1PR1, S1PR2 | S1PR1 2/4885CA12 4409/4885CA1 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.